Group 1 - The report indicates that the recent market adjustment pressure has been released, leading to a rebound, with popular sectors experiencing valuation recovery [6] - It maintains a cautiously optimistic view for February, suggesting that while the A-share index may struggle, there is potential for valuation recovery in the H-share market [6] - The report emphasizes the importance of mid-cap blue-chip stocks, particularly in the agricultural sector, as they are expected to continue performing well due to their risk characteristics [6] Group 2 - The renewable energy sector is highlighted as a cornerstone for carbon reduction, with significant growth expected in wind and solar installations during the 14th Five-Year Plan period [3] - The report anticipates over 50% growth in energy storage installations by 2025, driven by high demand in the renewable energy sector [3] - It suggests focusing on high-growth technology-related stocks within the renewable energy space [3] Group 3 - The report discusses the increasing certainty of mass production for humanoid robots, particularly with Tesla's advancements in this area [4] - It identifies investment opportunities in components related to robotics, such as sensors and flexible protective layers, as the industry moves towards more human-like robots [4] - Companies with proven manufacturing and management capabilities in automotive and machinery parts are expected to gain higher market shares [4]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved projects, which are anticipated to contribute positively to future revenues [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in critical therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery expected in subsequent years [6][12]. - The net profit attributable to the parent company is forecasted to be a loss of 53 million CNY in 2024, with a gradual return to profitability by 2026 [6][12]. - The earnings per share (EPS) is expected to drop to -0.63 CNY in 2025, before recovering to 0.37 CNY in 2026 and 0.61 CNY in 2027 [6][12]. - The gross margin is projected to decrease from 65.5% in 2023 to 52.0% in 2024, with a gradual recovery thereafter [6][12].

Group 1 - The report maintains a positive outlook on mid-cap blue chips, with a focus on price increases in the chemical and agricultural sectors [6][27] - Liquidity expectations are shifting, leading to increased volatility in non-ferrous metals, while the demand for industrial products driven by AI capital expenditure is expected to support price increases in cyclical goods [6][27] - Agricultural products are anticipated to experience a comprehensive price increase due to upstream price transmission and a tight supply-demand balance in major commodities like sugar, corn, and oilseeds [12][27] Group 2 - The trading sentiment across large, mid, and small-cap stocks has cooled, but medium-term uncertainty remains relatively stable [17][27] - The trend for mid-cap blue chips related to cyclical sectors (non-ferrous metals and basic chemicals) remains strong, while media and defense industries are showing strengthening trends [20][27] - Short-term uncertainty is rising for non-ferrous metals and petrochemicals, while medium-term uncertainty for basic chemicals is stable and for agriculture is declining [23][27]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved products, which are anticipated to contribute to stable revenue growth as they enter commercialization [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in key therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery to 889 million CNY by 2027 [6]. - The net profit attributable to the parent company is expected to turn negative in 2024 and 2025, with forecasts of -53 million CNY and -69 million CNY respectively, before recovering to 67 million CNY in 2027 [6]. - The earnings per share (EPS) is forecasted to be -0.63 CNY in 2025, with a recovery to 0.61 CNY by 2027 [6]. - The gross margin is expected to decrease from 65.5% in 2023 to 52.0% in 2024, before gradually improving to 56.4% by 2027 [6].

基金研究 | 专题报告 沃土生金春潮起，农业擎旗续周期 行业 ETF 配置系列报告之一 研究结论 风险提示 宏观经济与产业政策变化超预期风险、主题炒作风险、量化模型滞后性风险等。本报告 结论完全基于公开的历史数据进行计算，对基金产品和基金管理人的研究分析结论并不 预示其未来表现，也不能保证未来的可持续性，亦不构成投资收益的保证或投资建议。 本报告不涉及证券投资基金评价业务，不涉及对基金产品的推荐，亦不涉及对任何指数 样本股的推荐。 报告发布日期 2026 年 02 月 03 日 | 东春鸣 | 执业证书编号：S0860525100002 | dongchunming@orientsec.com.cn | | --- | --- | --- | | 021-63326320 | 王继恒 | 执业证书编号：S0860525090004 | | wangjiheng@orientsec.com.cn | 0755-82819271 | | 主动权益基金仓位跟踪周报(20260130) 2026-02-02 主动权益基金仓位跟踪周报(20260123) 2026-01-26 多视角看近期 ETF 市场持续放量现象 2 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Group 1 - The report indicates that the recent market adjustment pressure has been released, leading to a rebound, with popular sectors experiencing valuation recovery after a rapid decline [6] - The report maintains a cautiously optimistic view for February, suggesting that while the A-share index may struggle, there is potential for valuation recovery in the H-share market [6] - The report emphasizes the importance of mid-cap blue-chip stocks with medium risk characteristics, particularly in the agricultural sector, which is expected to continue its strength [6] Group 2 - The report highlights that during the "14th Five-Year Plan" period, China's wind and solar installations are expected to maintain high growth rates, with specific segments like offshore wind power and perovskite solar cells showing significant growth potential [6] - It forecasts that energy storage installations will achieve over 50% growth by 2025, driven by the high demand for renewable energy [6] - The report identifies high-growth technology-related stocks in the renewable energy sector as key investment opportunities [6] Group 3 - The report discusses the upcoming mass production of humanoid robots by Tesla, indicating increased certainty in this area, particularly regarding dexterous hands and the humanization of robots [4] - It suggests that the demand for components such as sensors and flexible protective layers will rise as robots become more human-like [4] - The report points out that companies with proven manufacturing and management capabilities in automotive and engineering machinery parts are likely to gain higher market shares [4]

Genie3 是否会对游戏及引擎公司造成商业 冲击？ ——游戏行业点评 传媒行业 行业研究 | 动态跟踪 国家/地区 中国 行业 传媒行业 报告发布日期 2026 年 02 月 03 日 看好（维持） | 项雯倩 | 执业证书编号：S0860517020003 | | --- | --- | | | 香港证监会牌照：BQP120 | | | xiangwenqian@orientsec.com.cn | | | 021-63326320 | | 李雨琪 | 执业证书编号：S0860520050001 | | | 香港证监会牌照：BQP135 | | | liyuqi@orientsec.com.cn | | | 021-63326320 | | 金沐阳 | 执业证书编号：S0860525030001 | | | 021-63326320 | | 沈熠 | | | --- | --- | | | 执业证书编号：S0860124120005 | | | shenyi1@orientsec.com.cn | | | 021-63326320 | | | | | 全栈式 AI 文娱工具陆续上线，平台型产品 | 202 ...

Investment Rating - The report maintains a "Positive" investment rating for the real estate industry, indicating an expectation of returns exceeding the market benchmark by more than 5% [5]. Core Viewpoints - The significance of the "three red lines" policy has diminished, suggesting that its policy objectives have largely been achieved, and the industry is transitioning from a "high-risk" model to high-quality development. Regulatory focus has shifted from preventing debt crises to stabilizing market expectations [3][7]. - Recent market data shows that the real estate sector index underperformed compared to the CSI 300 index, with a weekly decline of 2.2% and a relative return of -2.3% [3][8]. - New home sales in 30 cities increased by 23% compared to the previous week, totaling 141 million square meters, although year-to-date sales are down 24% [3][8]. Summary by Sections Market Performance - The real estate sector index has shown a weekly decline of 2.2%, underperforming the CSI 300 index by 2.3% [3][8]. - New home sales in 30 cities reached 141 million square meters, a 23% increase from the previous week, but a 24% decrease year-on-year [3][8]. Sales Data - New home sales increased in the fifth week compared to the fourth week, while second-hand home sales slightly decreased. The new home sales in 30 cities showed a 23% week-on-week increase, but a 24% year-to-date decline [3][8]. - Second-hand home sales in 18 cities totaled 17,000 units, a 2% decrease from the previous week, but a 14% year-to-date increase [3][8]. Investment Recommendations - The report suggests focusing on three categories of investment opportunities: 1. Quality developers with low historical burdens and strong sales growth expectations [4]. 2. Commercial real estate operations, particularly shopping centers that can maintain growth in a slowing economy [4]. 3. Real estate brokerage platforms that benefit from scale and brand advantages, which can enhance performance during market recovery [4].

研究结论 固定收益 | 专题报告 中等期限票息品种还可继续挖掘 2026 年 2 月小品种策略 风险提示 政策变化超预期；信用风险暴露超预期；ABS 发行及投资热度不及预期；数据统计可能 存在遗误 报告发布日期 2026 年 02 月 03 日 | 齐晟 | 执业证书编号：S0860521120001 | | --- | --- | | | 香港证监会牌照：BXF200 | | | qisheng@orientsec.com.cn | | | 010-66210535 | | 杜林 | 执业证书编号：S0860522080004 | | | dulin@orientsec.com.cn | | | 010-66210535 | | 王静颖 | 执业证书编号：S0860523080003 | | | wangjingying@orientsec.com.cn | | | 021-63326320 | | 徐沛翔 | 执业证书编号：S0860525070003 | | | xupeixiang@orientsec.com.cn | | | 021-63326320 | | 结汇如何影响资金面和存单：固定收益市 | ...